High-dose 166Ho-DOTMP in myeloablative treatment of multiple myeloma: Pharmacokinetics, biodistribution, and absorbed dose estimation

Journal of Nuclear Medicine

Volumn 43, Issue 10, 2002, Pages 1383-1390

  Rajendran, Joseph G ^a   Eary, Janet F ^a   Bensinger, William ^a   Durack, Larry D ^a   Vernon, Cheryl ^a   Fritzberg, Alan ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

emitters; Dosimetry; Myeloablation; Myeloma; Radionuclide therapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAMETHYLENEPHOSPHONIC ACID; HOLMIUM; MELPHALAN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAKIS(METHYLENEPHOSPHONIC ACID); 1,4,7,10-TETRAAZACYCLODODECANE-1,4,7,10-TETRAKIS(METHYLENEPHOSPHONIC ACID); ALKYLATING AGENT; ORGANOPHOSPHORUS COMPOUND; RADIOISOTOPE;

ADULT; AGED; ARTICLE; BETA RADIATION; BLADDER; BONE; BONE MARROW; CLINICAL ARTICLE; CLINICAL TRIAL; DOSIMETRY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MEGADOSE; GAMMA RADIATION; HUMAN; INJECTION; KIDNEY; MULTICENTER STUDY; MULTIPLE MYELOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY CONTROL; WHOLE BODY RADIATION; BONE MARROW PURGING; FEMALE; MALE; MIDDLE AGED; RADIATION DOSE; RADIOMETRY; TISSUE DISTRIBUTION;

ANTINEOPLASTIC AGENTS, ALKYLATING; BONE MARROW PURGING; FEMALE; HOLMIUM; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; ORGANOPHOSPHORUS COMPOUNDS; RADIOISOTOPES; RADIOMETRY; RADIOTHERAPY DOSAGE; TISSUE DISTRIBUTION;

EID: 0036771849     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med. 1994;330:484-489.
2. Alexanian R, Dimopoulous M, Smith T, et al. Limited value of myeloablative therapy for late multiple myeloma. Blood. 1994;83:512-516.
3. Barlogie B, Vesole D, Jaganath S. Salvage therapy for multiple myeloma: the University of Arkansas experience. Mayo Clin Proc. 1994;69:787-795.
4. Barlogie B, Alexanian R, Dick KA, et al. High-dose chemotherapy and autologous bone marrow transplantation for resistant myeloma. Blood. 1987;70:869-872.
5. Davis LP, Porter AT. Systemic radionuclide therapy: nuclear medicine's role in the palliation of painful bone metastases. In: Freeman LM, ed. Nuclear Medicine Annual. New York, NY: Raven Press; 1995:169-184.
6. Browne E, Firestone RB. Table of radioactive isotopes. New York, NY: Wiley; 1986:1-900.
7. Collins C, Eary JF, Donaldson G, et al. Samarium 153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/Il trial. J Nucl Med. 1993;34:1839-1844.
8. Turner JH, Claringbold PG, Hetherington EL, et al. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases. J Clin Oncol. 1989;7:1926-1931.
9. Graham MC, Scher HI, Liu G, et al. Rhenium 186 labeled hydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancer. Clin Cancer Res. 1999;5:1307-1318.
10. Appelbaum FR, Sandmaier B, Brown PA, et al. Myelosuppression and mechanism of recovery following administration of samarium 153-EDTMP. Antibody Immunoconjugates Radiopharm. 1988;1:263-270.
11. 166Ho EDTMP. Blood. 1992;80:1608-1613.
12. Parks NJ, Kawakami TG, Avila MJ, et al. Bone marrow transplantation in dogs after radioablation with a new Ho-166 amino phosphonic acid bone seeking agent (DOTMP). Blood. 1993;82;318-325.
13. Bayouth JE, Macey DJ. Dosimetry considerations of bone seeking radionuclides for marrow ablation. Med Phys. 1993;20:1089-1096.
14. Garlich JR, McMillan K, Masterson TT, et al. Chemistry of novel macrocyclic aminophosphonic acid chelates of rare earth radionuclides and their in vivo biodistribution [abstract]. J Nucl Med. 1993;34(suppl):244P.
15. Eary JF, Collins C, Stabin M, et al. Samarium-153 EDTMP biodistribution and dosimetry estimation. J Nucl Med. 1993;34:1031-1036.
16. Bayouth JE, Macey DJ, Kasi LP, et al. Pharmacokinetics, dosimetry and toxicity of holmium-166 DOTMP for bone marrow ablation in multiple myeloma. J Nucl Med. 1995;36:730-737.
17. Basic anatomical and physiological data for use in radiological protection: the skeleton - a report of a Task Group of Committee 2 of the International Commission on Radiological Protection. Ann ICRP. 1995;25:1-80.
18. Bayouth JE, Macey DJ, Boyer Al, et al. Radiation dose distribution with the bone marrow of patients receiving holmium-166 labeled phosphonate for marrow ablation. Med Phys. 1995;22:743-753.
19. 166Holmium-DOTMP plus standard high dose chemotherapy (HDC) with autologous transplant produce high rates of complete remission in multiple myeloma patients: an updated report of a phase I/II study [abstract]. Proc Am Soc Clin Oncol. 2001;20:18.
20. Eary JF, Press OW, Badger CC, et al. Imaging and treatment of B-cell lymphoma.J Nucl Med. 1990;31:1257-1268.
21. Louvinger R, Budinger TF, Watson EE. MIRD primer for absorbed dose calculations. Revised ed. New York, NY: Society of Nuclear Medicine; 1991:1-21.
22. Fogelman I, Pearson DW, Bessent RG, Tofe AJ, Francis MD. A comparison of skeletal uptakes of three diphosphonates by whole-body retention: concise communication. J Nucl Med. 1981;22:880-883.
23. Bayouth JE, Macey DJ, Kasi LP, et al. Dosimetry and toxicity of samarium-153 EDTMP administered for bone pain due to skeletal metastases. J Nucl Med. 1994;35:63-69.